The caption of Fig. 1 was corrected from “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemiafree survival (c, LFS), and overall survival(d, OS) patients receiving post-transplant cyclophosphamide (PTCy) versus Cyclosporine A (CSA) / methotrexate (MTX)” to “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival(c, LFS), and overall survival (d, OS) of patients receiving reduced intensity versus myeloablative conditioning regimen”. The original article has been corrected.
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (Bone Marrow Transplantation, (2022), 57, 7, (1116-1123), 10.1038/s41409-022-01693-8)
Ciceri F.;
2022-01-01
Abstract
The caption of Fig. 1 was corrected from “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemiafree survival (c, LFS), and overall survival(d, OS) patients receiving post-transplant cyclophosphamide (PTCy) versus Cyclosporine A (CSA) / methotrexate (MTX)” to “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival(c, LFS), and overall survival (d, OS) of patients receiving reduced intensity versus myeloablative conditioning regimen”. The original article has been corrected.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
s41409-022-01834-z.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Copyright dell'editore
Dimensione
474.5 kB
Formato
Adobe PDF
|
474.5 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.